Skip to main content

Month: March 2026

XORTX Announces Results of Annual and Special Meeting of Shareholders

CALGARY, Alberta, March 26, 2026 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“XORTX” or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, is pleased to announce the results of its annual and special meeting of shareholders (the “Meeting”) held Tuesday, March 24, 2026. A total of 2,407,148 common shares of the Company were represented at the Meeting, representing approximately 35% of the total number of common shares of the Company issued and outstanding. All matters presented for approval at the Meeting were duly authorized and approved including election of all five management nominees (Anthony Giovinazzo (Chair), Allen Davidoff (CEO), Mika Grasso, Richard Grieve and George...

Continue reading

STMicroelectronics Reports on Resolutions to be Proposed at the 2026 Annual General Meeting of Shareholders

STMicroelectronics Reports on Resolutions to be Proposed at the 2026 Annual General Meeting of Shareholders Amsterdam, March 26, 2026 – STMicroelectronics (NYSE: STM), a global semiconductor leader serving customers across the spectrum of electronics applications, announced the resolutions to be submitted for adoption at the Annual General Meeting of Shareholders (AGM) which will be held in Amsterdam, the Netherlands, on May 27, 2026. The resolutions, proposed by the Supervisory Board, are:The adoption of the Company’s statutory annual accounts for the year ended December 31, 2025, prepared in accordance with International Financial Reporting Standards (IFRS). The 2025 statutory annual accounts1 were filed with the Netherlands Authority for the Financial Markets (AFM) on March 26, 2026 and are posted on the Company’s website...

Continue reading

Datacentrex Announces Pricing of $20.17 Million Confidentially Marketed Public Offering at $2.00 per Share

SALT LAKE CITY, March 26, 2026 (GLOBE NEWSWIRE) — Datacentrex, Inc. (Nasdaq: DTCX) (“Datacentrex” or the “Company”), a digital infrastructure and capital deployment company that owns and operates Scrypt compute assets and evaluates strategic transactions across asset-backed operating businesses, today announced the pricing of its confidentially marketed public offering (the “Offering”) of common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock, at a public offering price of $2.00 per share (inclusive of the pre-funded warrant exercise price). The Company expects to receive aggregate gross proceeds of $20.17 million from the Offering, before deducting placement agent fees and other related expenses. The Offering is expected to close on or about March 30,...

Continue reading

Sanuwave Announces Record Revenues and Financial Results for Q4 and Full Year 2025

Q4 2025 revenues were $13.4 million, up 29.7% from Q4 2024. This was an all-time quarterly record for the Company. Full year 2025 revenues were $44.1 million up 35.0% from full year 2024 revenues. This was an all-time annual record for the Company. Q4 2025 gross margin was 74.7%, versus 77.9% in Q4 2024 and 77.6% in Q3 2025. Full year 2025 gross margin was 77.1% versus 75.2% in 2024. GAAP Operating Income was $2.0 million for Q4 2025 and $4.9 million for full year 2025. Company provides guidance for revenues of $9.6-10.3 million (an increase of 3-10%) for Q1 2026 as compared to Q1 2025 and initiates full year 2026 revenue guidance of 16-25% growth vs 2025 ($51.0-55.0 million). EDEN PRAIRIE, Minn., March 26, 2026 (GLOBE NEWSWIRE) — Sanuwave Health, Inc. (the “Company” or “Sanuwave”) (NASDAQ: SNWV), a leading...

Continue reading

DBV Technologies Announces Filing of 2025 Annual Report on Form 10-K and Universal Registration Document

Châtillon, France, March 26, 2026 DBV Technologies Announces Filing of 2025 Annual Report on Form 10-K and Universal Registration Document DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a late-stage biopharmaceutical company (the “Company”), today announced the filing, for the year ended December 31, 2025, of its Annual Report on Form 10-K with the U.S. Securities and Exchange Commission (“SEC”) and its Universal Registration Document (“ 2025 URD”) with the French market authority, “Autorité des Marchés Financiers” (“AMF”). In compliance with French law, the following information are included in the 2025 URD :The 2025 annual financial report; The Board of Directors’ corporate governance report (“rapport sur le gouvernement d’entreprise”) required under Article L. 225-37 of the French Commercial...

Continue reading

Firan Technology Group Corporation (“FTG”) Announces First Quarter 2026 Earnings Release and Conference Call Dates

TORONTO, March 26, 2026 (GLOBE NEWSWIRE) — Firan Technology Group Corporation (TSX: FTG) (OTCQX: FTGFF) (“FTG”) will release the first quarter 2026 financial results after the market closes on Wednesday, April 8, 2026. The Corporation will host a live conference call on Thursday, April 9, 2026, at 8:30am (Eastern Time) to discuss the first quarter of 2026 financial results. Anyone wishing to participate in the call should dial 289-514-5100 or 1-800-717-1738, Conference ID 33073, and identify that you are calling to participate in the FTG conference call. The Chairperson is Mr. Brad Bourne. A replay of the call will be available until May 11, 2026, and will be available on the FTG website at www.ftgcorp.com. The number to call for a rebroadcast is 289-819-1325 or 1-888-660-6264, Playback Passcode 33073. ABOUT FIRAN TECHNOLOGY GROUP...

Continue reading

Lassonde Industries Inc. announces its Q4 and fiscal 2025 results

ROUGEMONT, Quebec, March 26, 2026 (GLOBE NEWSWIRE) — Lassonde Industries Inc. (TSX: LAS.A) (“Lassonde” or the “Corporation”) today announced its financial results for its fourth quarter and year ended December 31, 2025. Financial Highlights:  Fourth quarters ended Years endedDec. 31,2025 Dec. 31,2024 ∆ Dec. 31,2025 Dec. 31,2024 ∆(in millions of dollars, unless otherwise indicated) $ $ $ $ $ $Sales 768.1   738.1   30.0   2,934.0   2,600.9   333.1  Gross profit 225.0   192.9   32.1   801.5   698.1   103.4  Operating profit 71.1   43.0   28.1   226.1   174.7   51.4  Profit 54.2   27.8   26.4   149.4   113.4   36.0  Attributable to: Corporation’s shareholders 54.0   27.1   26.9   149.7   114.1   35.6  Non-controlling interests 0.2   0.7   (0.5 ) (0.3 ) (0.7 ) 0.4  EPS (in $) 7.92   3.97   3.95   21.94   16.73   5.21  Weighted...

Continue reading

LeonaBio Reports Full Year 2025 Financial Results and Provides Business Update

Acquired License to Phase 3 Lasofoxifene Development Program of Novel Selective Estrogen Receptor Modulator (SERM), a Potential Multi-Billion Dollar Opportunity as Treatment Option for Breast Cancer Patients with ESR1-Mutations Received Gross Proceeds of $90 Million in Private Placement Financing of Common Stock and Warrants with Cash-Exercisable Warrants Potentially Providing up to an Additional $146 Million to Support Development of Lasofoxifene Through Key Clinical and Regulatory Milestones Expect to Complete Enrollment of Phase 3 Clinical Trial of Lasofoxifene in ER-positive (ER+), HER2-negative, ESR1-mutated Metastatic Breast Cancer in 4Q 2026 with Topline Data Anticipated in 2H 2027 On-track to Initiate Phase 2 Proof-of-Concept Study of ATH-1105 in ALS patients in 2H 2026 BOTHELL, Wash., March 26, 2026 (GLOBE NEWSWIRE) — LeonaBio,...

Continue reading

KULR Technology Group Sets Fourth Quarter and Full Year 2025 Earnings Call for Tuesday, March 31, 2026 at 4:30 p.m. ET

HOUSTON, March 26, 2026 (GLOBE NEWSWIRE) — KULR Technology Group, Inc. (NYSE American: KULR) (the “Company” or “KULR”), the advanced battery intelligence solution for autonomous platforms, digital infrastructure, e-mobility, and spaceflight applications, will hold a conference call on Tuesday, March 31st at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) to discuss its financial results for the fourth quarter and full year ended December 31, 2025. The financial results will be issued in a press release prior to the call. KULR management will host the conference call, followed by a question-and-answer period. Interested parties can submit relevant questions prior to the call to Stuart Smith via email: ir@kulr.ai by 11:00 a.m. ET on Sunday, March 29th, 2026. Mr. Smith will compile a list of questions and submit...

Continue reading

Thor Equities Acquires Prime Mixed-Use Asset at 1165 Broadway in NYC’s NoMad District

Firm expands portfolio with $56 Million purchase of 58,000-SF office and retail property New York, NY, March 26, 2026 (GLOBE NEWSWIRE) — Thor Equities, a global leader in real estate development, leasing, and asset management, today announced the acquisition of 1165 Broadway, a 58,000-square-foot, mixed-use office and retail property for $56 Million. Located in the heart of Manhattan’s NoMad District, the asset is 100% occupied by a strong roster of creative retail and office tenants. Situated between 27th and 28th Streets, 1165 Broadway is a historic building designed by Charles Mellon in 1867, originally home to the Coleman House Hotel. The fully leased property offers exceptional visibility, transit access, and close proximity to Madison Square Park. Current tenants include global luxury brand Christian Louboutin, premium skincare...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.